Document is current
Any future updates will be listed below
-
Authors
Ackerman, Shelley E.
Pearson, Cecelia I.
Gregorio, Joshua D.
Gonzalez, Joseph C.
Kenkel, Justin A.
Hartmann, Felix J. https://orcid.org/0000-0002-4174-2276
Luo, Angela
Ho, Po Y.
LeBlanc, Heidi
Blum, Lisa K. https://orcid.org/0000-0002-7921-8939
Kimmey, Samuel C. https://orcid.org/0000-0002-5742-4037
Luo, Andrew
Nguyen, Murray L.
Paik, Jason C.
Sheu, Lauren Y. https://orcid.org/0000-0003-2038-9909
Ackerman, Benjamin
Lee, Arthur
Li, Hai
Melrose, Jennifer
Laura, Richard P.
Ramani, Vishnu C.
Henning, Karla A. https://orcid.org/0000-0002-1099-6089
Jackson, David Y.
Safina, Brian S.
Yonehiro, Grant
Devens, Bruce H.
Carmi, Yaron https://orcid.org/0000-0002-0972-0616
Chapin, Steven J.
Bendall, Sean C. https://orcid.org/0000-0003-1341-2453
Kowanetz, Marcin
Dornan, David
Engleman, Edgar G.
Alonso, Michael N. https://orcid.org/0000-0003-3859-7669
- License Information
-
More Information
Article History
Received: 20 December 2019
Accepted: 30 September 2020
First Online: 7 December 2020
Competing interests
: All authors affiliated with Bolt Biotherapeutics are current or former employees. Bolt Biotherapeutics-affiliated authors and Y.C. may hold stock options and/or equity in Bolt Biotherapeutics. E.G.E. is a founder and shareholder of Bolt Biotherapeutics and a member of the company’s board of directors. S.E.A., J.A.K., A. Lee, D.Y.J., E.G.E. and M.N.A. are Stanford- and/or Bolt Biotherapeutics-affiliated inventors of , which discloses T785-containing ISACs.
